Retinal implants have gained increasing interest since it was demonstrated in acute trials that completely blind subjects do have light perception upon electrical stimulation of the inner surface ...

Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal ...

Vivani Medical, Inc. (NASDAQ:VANI) said it intends to spin off Cortigent, Inc., a division that develops brain implant ...

A rare, progressive neurodegenerative disease associated with loss of macular photoreceptors in the retinas, MacTel type 2 ...

With a U.S. green light for its encapsulated cell therapy technology in the bag, privately held biotech Neurotech ...

New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...

But with the help of a retinal implant, or "bionic eye" called Argus II, some patients with the rare disorder are regaining their sight. A clinical trial of the device has been ongoing in 10 ...

While there is currently no cure for RP, certain treatments such as gene therapy, retinal implants, and vitamin A supplementation can help slow its progression. Ongoing research in areas like stem ...

The recommended dose is one ENCELTO implant per affected eye containing 200,000 to 440,000 allogeneic retinal pigment epithelial cells expressing recombinant human ciliary neurotropic factor (rhCNTF).

Phase 3 trials demonstrated ENCELTO significantly slowed macular photoreceptor loss in MacTel patients over 24 months.

we examined the surgical outcomes of patients with glaucoma requiring a scleral buckle for retinal detachment repair who underwent concomitant scleral buckle and Baerveldt glaucoma implant (BGI ...

Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced that the U.S. Food and Drug Administration (FDA), has ...